Scynexis

Canaccord Genuity acts as joint bookrunner for US$36.0 million follow-on offering of common stock by SCYNEXIS, Inc.

Canaccord Genuity is pleased to announce that on April 28, 2015, it completed a follow-on offering of common stock for SCYNEXIS, Inc. (NASDAQ: SCYX).  The company issued a total of 4,675,324 shares of common stock at a price of $7.70 per share. In addition, SCYNEXIS has granted the underwriters a 30-day option to purchase up to an additional 701,298 shares of common stock at the initial public offering price. Canaccord Genuity acted as joint bookrunner for the offering. SCYNEXIS intends to use the net proceeds from this offering for working capital, capital expenditures and other general corporate purposes including the development of SCY-078.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans.